Eric Kelsic

Company: Dyno Therapeutics

Job title: Founder & Chief Executive Officer

Seminars:

10:00AM Case Study: Next-Generation AAVs for CNS Targeting: Enhancing Precision While Reducing Liver Tropism & Immunogenicity 10:00 am

• Exploring novel capsid modifications that improve blood-brain barrier crossing and increase therapeutic efficacy in neurological disorders • Strategies to substantially detarget the liver, lowering systemic toxicity and reducing immune activation • How advanced AAV engineering can mitigate immune responses, improve patient tolerability, and enhance long-term therapeutic successRead more

day: Conference Day 1